These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 36233030)

  • 21. Mucopolysaccharidosis III: Molecular basis and treatment.
    Spahiu L; Behluli E; Peterlin B; Nefic H; Hadziselimovic R; Liehr T; Temaj G
    Pediatr Endocrinol Diabetes Metab; 2021; 27(3):201-208. PubMed ID: 34743503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mental retardation in mucopolysaccharidoses correlates with high molecular weight urinary heparan sulphate derived glucosamine.
    Coppa GV; Gabrielli O; Zampini L; Maccari F; Mantovani V; Galeazzi T; Santoro L; Padella L; Marchesiello RL; Galeotti F; Volpi N
    Metab Brain Dis; 2015 Dec; 30(6):1343-8. PubMed ID: 26016623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The abnormal accumulation of heparan sulfate in patients with mucopolysaccharidosis prevents the elastolytic activity of cathepsin V.
    Chazeirat T; Denamur S; Bojarski KK; Andrault PM; Sizaret D; Zhang F; Saidi A; Tardieu M; Linhardt RJ; Labarthe F; Brömme D; Samsonov SA; Lalmanach G; Lecaille F
    Carbohydr Polym; 2021 Feb; 253():117261. PubMed ID: 33278943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry.
    Tomatsu S; Montaño AM; Oguma T; Dung VC; Oikawa H; Gutiérrez ML; Yamaguchi S; Suzuki Y; Fukushi M; Barrera LA; Kida K; Kubota M; Orii T
    Mol Genet Metab; 2010 Feb; 99(2):124-31. PubMed ID: 19932038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding of heparan sulfate to human cystatin C modulates inhibition of cathepsin L: Putative consequences in mucopolysaccharidosis.
    Denamur S; Chazeirat T; Maszota-Zieleniak M; Vivès RR; Saidi A; Zhang F; Linhardt RJ; Labarthe F; Samsonov SA; Lalmanach G; Lecaille F
    Carbohydr Polym; 2022 Oct; 293():119734. PubMed ID: 35798429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders.
    McGlynn R; Dobrenis K; Walkley SU
    J Comp Neurol; 2004 Dec; 480(4):415-26. PubMed ID: 15558784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice.
    Langford-Smith K; Arasaradnam M; Wraith JE; Wynn R; Bigger BW
    Mol Genet Metab; 2010 Mar; 99(3):269-74. PubMed ID: 19926322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry.
    Kubaski F; Mason RW; Nakatomi A; Shintaku H; Xie L; van Vlies NN; Church H; Giugliani R; Kobayashi H; Yamaguchi S; Suzuki Y; Orii T; Fukao T; Montaño AM; Tomatsu S
    J Inherit Metab Dis; 2017 Jan; 40(1):151-158. PubMed ID: 27718145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic testing of Mucopolysaccharidoses disease using multiplex PCR- based panels of STR markers: in silico analysis of novel mutations.
    Shafaat M; Hashemi M; Majd A; Abiri M; Zeinali S
    Metab Brain Dis; 2019 Oct; 34(5):1447-1455. PubMed ID: 31236806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI.
    Auray-Blais C; Bhérer P; Gagnon R; Young SP; Zhang HH; An Y; Clarke JT; Millington DS
    Mol Genet Metab; 2011 Jan; 102(1):49-56. PubMed ID: 20934363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses.
    Tomatsu S; Gutierrez MA; Ishimaru T; Peña OM; Montaño AM; Maeda H; Velez-Castrillon S; Nishioka T; Fachel AA; Cooper A; Thornley M; Wraith E; Barrera LA; Laybauer LS; Giugliani R; Schwartz IV; Frenking GS; Beck M; Kircher SG; Paschke E; Yamaguchi S; Ullrich K; Isogai K; Suzuki Y; Orii T; Noguchi A
    J Inherit Metab Dis; 2005; 28(5):743-57. PubMed ID: 16151906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caprine mucopolysaccharidosis-IIID: clinical, biochemical, morphological and immunohistochemical characteristics.
    Jones MZ; Alroy J; Boyer PJ; Cavanagh KT; Johnson K; Gage D; Vorro J; Render JA; Common RS; Leedle RA; Lowrie C; Sharp P; Liour SS; Levene B; Hoard H; Lucas R; Hopwood JJ
    J Neuropathol Exp Neurol; 1998 Feb; 57(2):148-57. PubMed ID: 9600207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses.
    Langereis EJ; Wagemans T; Kulik W; Lefeber DJ; van Lenthe H; Oussoren E; van der Ploeg AT; Ruijter GJ; Wevers RA; Wijburg FA; van Vlies N
    PLoS One; 2015; 10(9):e0138622. PubMed ID: 26406883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.
    McCarty DM; DiRosario J; Gulaid K; Killedar S; Oosterhof A; van Kuppevelt TH; Martin PT; Fu H
    Metab Brain Dis; 2011 Mar; 26(1):9-19. PubMed ID: 21225451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
    Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
    Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
    Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
    Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses.
    Kaidonis X; Liaw WC; Roberts AD; Ly M; Anson D; Byers S
    Eur J Hum Genet; 2010 Feb; 18(2):194-9. PubMed ID: 19690583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain.
    Dekaban AS; Constantopoulos G
    Acta Neuropathol; 1977 Jul; 39(1):1-7. PubMed ID: 409090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses.
    Lin HY; Lee CL; Lo YT; Wang TJ; Huang SF; Chen TL; Wang YS; Niu DM; Chuang CK; Lin SP
    Mol Genet Genomic Med; 2018 Nov; 6(6):982-992. PubMed ID: 30296009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.